| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Trade names | Kostaive |
| Other names | ARCT-154, MRNA-2105 |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Zapomeran, sold under the brand nameKostaive is a self-amplifyingmRNA-basedCOVID-19 vaccine.[1] It contains a self-amplifying mRNA that encodes theSARS-CoV-2 spike protein.[1] Self-amplifying means that the mRNA also carries instructions to make a protein calledreplicase.[1]
Zapomeran was approved for medical use in Japan in November 2023, and it is the first self-amplifying mRNA-based COVID-19 vaccine to be approved.[3][4] Zapomeran was authorized for medical use in the European Union in February 2025.[1][2]
Zapomeran is used to provide protection againstCOVID-19, caused by infection with theSARS-CoV-2 virus.[1]
Kostaive was approved for medical use in Japan in November 2023.[5][6][7]
In December 2024, theCommittee for Medicinal Products for Human Use of theEuropean Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kostaive, a vaccine intended for the prevention of COVID-19 in adults.[1] The applicant for this medicinal product is Arcturus Therapeutics Europe B.V.[1] Zapomeran was authorized for medical use in the European Union in February 2025.[1][2]
Zapomeran is theinternational nonproprietary name.[8][9]
.svg)